EGFR and neoplasm: While, in a clinical setting, these cells are irradiated before application, the ensuing lack of in vivo expansion and long-term engraftment may be compensated by repeated treatments [50], and can be considered an additional safety feature, especially when targeting tumor-associated antigens like EGFR that are also expressed in healthy tissues.